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Synthetic cathinones constitute one of the most commonly abused new psychoactive substances. 
The rapid development of synthetic cathinones creates a challenge for forensic laboratories to 
develop and maintain analytical methods for identifying and quantifying synthetic cathinones and 
their metabolites in illicit drug and toxicological samples. The characterisation of synthetic cathinone 
metabolites is therefore important for both developing an understanding of their pharmacokinetics 
and for identifying unique metabolites that could be used for identification. In this review, the 
current state of knowledge regarding the metabolism of synthetic cathinones will be discussed; 
focussing primarily on the human in vitro and in vivo metabolism, with the objective of providing a 
systematic overview of the currently known metabolic profiles. In addition to this, the mass-spectral 
dissociation fragmentation pathways of synthetic cathinones will be reviewed in an attempt to 
identify common fragmentation patterns that may assist in the identification of previously 
unidentified synthetic cathinones.  
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CHAPTER ONE: Introduction        
 
Novel psychoactive substances (NPS) constitute an evolving mixture of substances that have 
received considerable attention and public concern over the past few years. Also referred to as 
“legal highs” or “designer drugs”, NPS are designed to reproduce the effects of controlled illicit 
substances such as cannabis, hallucinogens and stimulants.1 NPS can be classified according to either 
their psychotropic effects, as stimulants, empathogens/entactogens, and hallucinogens, or the 
chemical family that they resemble as phenethylamines, tryptamines, synthetic cathinones and 
synthetic cannabinoids.2 Typically, these substances are analogues or chemical derivatives of already 
scheduled illicit substances such as cannabis, hallucinogens and stimulants. These analogues are 
synthesised with structural modifications making them structurally different and as such can 
circumvent existing legal restrictions.2, 3 As a result, some NPS can be marketed and sold as “legal 
highs”, increasing the widespread accessibility and availability of these substances.3 
Over the last decade an exponential increase in the number of NPS identified and monitored by 
international bodies has been observed.1, 4, 5 Between 2005 and 2015, more than 560 NPS have been 
observed by the European Union Early Warning System (EU-EWS) of The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA).5 As of 2016, the United Nations Office on Drugs and 
Crime (UNODC) has reported the presence of over 643 NPS in 101 countries; an unparalleled 
globalisation rate.3, 6 In Australia, the most commonly abused NPS are the synthetic cannabinoids, 
synthetic cathinones, phenethylamines and tryptamines, with the synthetic cannabinoids and 
synthetic cathinones representing the greatest proportion of seized substances.7 Between 2015 and 
2016 cathinone-type substances accounted for 33.3% of analysed seizure samples; a trend similar to 
that observed in some European countries.4, 8 
 Given the rate at which new cathinone derivatives are emerging on the drug market their legal 
status has become the subject of considerable legislation over recent years. A number of European 
countries and the USA have imposed regulations that target individual cathinone derivatives.9 In 
Australia legislation has been introduced that broadly states that criminal offences that apply for 
already existing scheduled drugs automatically apply to substances deemed to be structurally 
similar.1 However, despite such regulations new cathinone derivatives are continuously being 
produced in clandestine laboratories, creating a difficulty for legislation to stay current.3 
The difficulty in attempting to regulate these substances lies in their rapid development, ease of 
synthesis and widespread availability, particularly through prominent advertisement and sale 
through online networks.3 Furthermore, the diversity of NPS in regards to both their psychotropic 
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effects and chemical structure creates challenges in the detection and identification these 
substances.3 Over the past few years the topic of synthetic cathinone derivatives has produced 
considerable research relating to the identification of new derivatives, their chemical behaviour and 
metabolism. This review will provide a systematic overview of the literature surrounding the 
chemistry, behaviour and the metabolism of synthetic cathinones focussing specifically on 
consolidating the current state of knowledge surrounding the human metabolic pathways of specific 
cathinone derivatives. Additionally, the structural characterisation of synthetic cathinones will be 
reviewed with a focus on the collision ionisation induced (CID) fragmentation patterns commonly 
encountered for synthetic cathinone derivatives. Knowledge of the fragmentation patterns of 
synthetic cathinones, and of fragment ions, could assist with the identification of previously 


































1.1 Cathinone pharmacology and mechanism of action 
 
Cathinone derivatives are analogues of the natural compound cathinone, a psychoactive stimulant 
found in the leaves of the Catha edulis plant commonly known as Khat.10 Due to its psychoactive 
effects, the practice of khat chewing has traditionally been used by many communities throughout 
the Horn of Africa, Yemen and in the Southwest Arabian Peninsula.10 The process of khat chewing 
involves chewing small bundles and shoots of khat to release the active constituents into the saliva 
before swallowing the plant material.11 While khat contains numerous non-cyclic nitrogen containing 
compounds it is believed that cathinone, a β-ketone phenylalkylamine, is the primary compound 
responsible for the psychoactive effects of khat.12 Cathinone can be considered a β-ketone analogue 
of amphetamine, which differs structurally  from amphetamine by the presence of a β-ketone in the 
α-position of the side chain of the cathinone (Figure 1).13 As such, cathinone and its derivatives 
produce a distinct cluster of pharmacological effects similar to amphetamine and 
methamphetamine. Primarily these include central nervous stimulant and sympathomimetic effects 
including euphoria, excitation, agitation, and increased sensory stimulation.10, 14 Synthetic derivatives 
of cathinones are commonly sold through online vendors and are typically marketed under 
alternative names of “Bath salts”, “Research chemicals” and “Plant food”. These substances are 
primarily available in a crystalline or powder form and are commonly administered by snorting, 
smoking, orally ingested or in a less common method by intravenous injection.15 
 
As cathinone derivatives possess a β-ketone structure they are less lipophilic than amphetamine and 
therefore typically require higher doses to achieve equivalent effects to that of amphetamines.16, 17 
Like amphetamines, cathinone and its derivatives exert effects by interacting with plasma 
membrane monoamine transporters such as dopamine transporter (DAT), noradrenaline transporter 
(NAT) and serotonin transporter (SERT).14 Cathinone derivatives can interact with monoamine 
transporters in two ways; as either monoamine transporter blockers or monoamine transporter 
substrates. Those acting as blockers exert their effects via the inhibition of monoamine re-uptake in 




a similar fashion to cocaine or 3,4-methylenedioxymethamphetamine (MDMA).18 The monoamine 
transporter substrates act via the preferential inhibition of monoamine reuptake, resulting in a 
decreased clearance of neurotransmitters—a mechanism similar to amphetamines.18, 19 In vitro 
studies performed using cell and synaptosomal preparations have demonstrated differences in the 
pharmacology of different cathinone derivatives as a result of differences in their affinity towards 
the aforementioned transporters. Therefore the structure of the derivatives will have an influence 




1.2 Chemical structure and classification of cathinone derivatives 
 
The basic cathinone structure lends itself easily to modifications at several different locations 
resulting in a wide array of cathinone derivatives.20 These modifications include the addition of 
various substituents at the R3 position on the aromatic ring, variation in the α-carbon substituent and 
N-alkylation at the R1 and R2 positions (Figure 2).16 Cathinone derivatives can be classified into four 
major groups based on their structure: N-alkylated compounds, methylenedioxy-substituted 










Figure 2: The generic structure of cathinone derivatives. 
The various points on the structure at which substituents 
are added are represented.16 
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1.2.1 N-alkylated cathinone derivatives 
 
The N-alkylated cathinone derivatives are a cluster of related compounds characterised by 
substituents at the R1 and/or R2 sites or compounds with an alkyl or halogen substituent at a position 
along the aromatic ring (R3).
9 This group of cathinones contains some of the first derivatives 
generated for therapeutic purposes, namely dimethylpropion and diethylpropion, which are N-
methylated and N-ethylated at the R2 position respectively (Figure 3).
10 Modifications in the length 
of the aliphatic chain can produce a range of derivatives that differ only by the number of carbons at 
the R4 position, such as buphedrone and pentedrone. Similarly, derivatives can differ by variation in 
the addition of methyl and ethyl groups at the R1 and R2 position (i.e. methylpropion, diethylpropion, 
ephedrone, ethcathinone etc.). Additionally, the insertion of halogen substituents at the aromatic 
ring, namely fluorine and chlorine, give derivatives such as flephedrone and bupropion (Figure 3); 
the latter of which has been investigated for potential therapeutic use. 9, 10, 16, 21  
  
 
Figure 3: The chemical structure of some common N-alkylated cathinone 




1.2.2 Methylenedioxy-N-alkylated derivatives 
 
This group encompasses N-methylated and N-ethylated compounds which result from an alkylation 
at the R1 and R4 positions with the addition of a methylenedioxy group at the aromatic ring (Figure 
4). Methylation at the R1 position produces methylone whilst addition of an ethyl group at the same 
site produces ethylone (Figure 4). Further ethylation and methylation of the R4 position results in 
butylone and pentylone respectively (Figure 4). Derivatives belonging to this group show structural 
similarity with 3,4-methylenedioxyamphetamines (MDAs) such as MDMA and MDEA (3,4-
methylenedioxyethamphetamine).10   
 
 
1.2.3 N-pyrrolidine substituted cathinone derivatives 
 
N-pyrrolidine cathinone derivatives are characterised by the presence of a pyrrolidinyl moiety at the 
nitrogen atom of the cathinone structure.22 While this group has the underlying natural cathinone 
structure, α-pyrrolidinopropiophenone (α-PPP) acts as the primary prototype for other cathinone 
derivatives within this group (Figure 5).16 For instance, α-PPP can be modified by extending the side 
chain at the R4 position to give α-pyrrolidinovalerophenone (α-PVP); a derivative in which the 
aliphatic chain is one carbon longer than α-PPP. The aliphatic chain of α-PVP can be shortened to 
give α-pyrrolidinobutyrophenone (α-PBP) or lengthened to give α‐pyrrolidinohexanophenone (α-
PHP) and α‐pyrrolidinooctanophenone (α-POP) (Figure 5). In addition to chain substituents, α-PPP 
can be modified by the addition of a phenyl substituent at the R3 and R4 position of the aromatic 
Figure 4: Chemical structure of 3,4-methylenedioxy-N-alkylated cathinone derivatives 
(A) and the structurally related MDAs (B).   MDMA 3,4-methylenedioxymethamphetamine; 
MDEA 3,4-methylenedioxyethamphetamine; MBDB 3,4-methylenedioxy-α-ethyl-N-
methylphenethylamine; MBDP 3,4-methylenedioxy-α-propyl-N-methylphenethylamine.10 
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ring; with the addition of methyl and methoxy groups resulting in the generation of 4-methyl-α-
pyrrolidinopropiophenone (MPPP) and 4-methoxy-α-pyrrolidinopropiophenone (MOPPP), 
respectively (Figure 5).23 Similarly, α-PVP can be modified by the addition of halogen, methoxy or 
methyl groups at the aromatic ring to give 4-fluoro α-PVP, 4-methoxy α-PVP, and 3,4-dimethoxy- α-
PVP, respectively. Additional modification, such as the replacement of the phenyl ring with other 
aromatic rings (i.e. thiophene) can  give other derivatives such as α-pyrrolidinopentiothiophenone 
(α-PVT).22 Interestingly, the high lipophilicity of the pyrrolidine ring has been suggested to increase 
the permeability of pyrrolidinyl substituted compounds through the blood-brain barrier, potentially 

























Figure 5: Chemical structures of the N-pyrrolidine cathinone derivatives and 3,4-methylenedioxy-N-
pyrrolidine cathinone derivatives. 3,4-MDPPP, 3,4-MDPBPand MDPV belong to the  3,4-










1.2.4 Methylenedioxy-N-pyrrolidine cathinone derivatives 
 
Structurally, 3,4-methylenedioxy-N-pyrrolidine cathinone derivatives resemble pyrrolidinyl 
derivatives with the addition of a methylenedioxy moiety at the 3,4 position of the aromatic ring 
(Figure 5). Derivatives belonging to this group include 3,4-methylenedioxy-α-
pyrrolidinopropiophenone (MDPPP), 3,4-methylenedioxy-α-pyrrolidinobutiophenone (MDPBP),  
3,4-methylenedioxypyrolvalerone (MDPV). The addition of a methyl or an ethyl group on the MDPPP 
molecule at the R4 position gives the MDPBP and MDPV derivatives, respectively (Figure 5).
25  
Structurally, these derivatives resemble those of MPPP, MPBP, and pyrovalerone (belonging to the 
N-pyrrolidine derivatives); the difference being the methylenedioxy ring substitution.  
 
 
1.3 Analytical methods for the identification of cathinone derivatives   
 
The number of structurally related cathinone derivatives that exist and their continuous emergence 
on the drug market poses an analytical challenge for forensic chemistry laboratories. The analysis of 
seized samples in forensic laboratories is performed in accordance with the guidelines outlined by 
the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG).26 This involves a 
combination of analytical techniques such as gas chromatography-mass spectrometry (GC-MS), 
liquid chromatography (LC), Fourier transform-infrared spectroscopy, and nuclear magnetic 
resonance spectroscopy for the identification of substances.27 The continuous emergence of newly-
synthesised synthetic cathinones however, poses a challenge for toxicological forensic laboratories 
to develop and maintain reliable analytical methods for the qualitative and quantitative 
identification of compounds in biological matrices. 
 
GC-MS analysis is a technique that involves the production of gas-phase ions using different 
ionisation techniques that are accelerated and separated in a mass analyser under a high vacuum 
according to the mass-to-charge-ratio (m/z).28 While conventional GC-MS methods have been used 
for drug analysis, traditional electron ionisation (EI) GC-MS suffers from extensive fragmentation in 
the ion source resulting in the absence of molecular ions.29 Additionally, it has been noted that to 
reliably detect some cathinone derivatives using GC-EI-MS methods derivatisation was necessary, a 
process which increases the cost and time of analysis.30 Recently, liquid-chromatography mass 
spectrometry (LC-MS) techniques have become increasingly used for drug analysis and metabolism 
studies, particularly when coupled to high-resolution-mass-spectrometry (HRMS) methods.28 The 
versatility of LC to be coupled with various analysers and the number of different analysers available 
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has resulted in the development of many analytical approaches for identifying metabolites. Among 
the most attractive methods is the use of ultra-high performance liquid chromatography (UHPLC) 
coupled with time-of-flight mass spectrometry (TOF-MS) and its quadruple analyser which separates 
ions according to velocity and the time-of-flight.27  
 
Tandem mass spectrometry (MS/MS) is often applied for the structural elucidation of cathinone 
derivatives, the determination of fragmentation pathways, and to determine elemental 
compositions.28 This technique primarily consists of two mass analyser interfaces; the first which 
isolates a precursor ion and the second which separates the product ions.28 Of the various scan 
modes available for tandem MS, the product ion scan mode is the most utilised for the identification 
of compounds.31  In this mode, a precursor ion is chosen and the product ions (i.e. fragment ions) are 
determined from the CID. CID is used to facilitate the fragmentation of precursor ions using 
collisions between low and high energy accelerated ions and collision gas.  When coupled with time-
of-flight mass analysers the introduced ions are accelerated into a flight tube by an electric field. 
These ions are then separated on the basis of their velocities as they travel through the flight tube, 
in the free-drift region.  An advantage of the QTOF-MS based methods is that they provide a broad 
mass range, high sensitivity and fast analysis time.9, 31 The combination of CID-MS with a high 
resolution mass spectrometer can provide information on the elemental composition of the 
molecule, the fragmentation patterns, and for the tentative identification of compounds without the 
need for reference standards—which are often unavailable for newly-emerged cathinones.28 
Overall, LC-MS methods are advantageous as they are able to assess a broad range of carious 
compounds without derivatisation of the compound.32 Additionally, softer ionisation techniques 
such as electrospray ionisation (ESI) produces less fragmentation in the ion source, which results in 
more useful spectra with more molecular ions. In HRMS, the protonated molecule can be used to 
estimate the chemical structure of a compound and/or fragments and therefore the presence of 
molecular ions is important for structural elucidation.32 Recently, HRMS has been employed in a 
number of studies for the identification and structural characterisation of synthetic cathinones.31 
Particularly, searching for common fragments using QTOF-MS is useful for investigating compounds 







1.4 Methods for metabolic profiling 
 
For both ethical and safety reasons controlled drug studies are often not performed with illicit drugs, 
therefore several in vitro and in vivo approaches have been employed for studying the metabolism 
of synthetic cathinones. In vitro methods often utilise systems such as fractions of liver homogenate 
and cell cultures to assess metabolic pathways.33 A number of approaches use fractions of drug 
metabolising tissues such as pooled human liver cytostol (pHLC), pooled human S9 fraction (pS9) and 
pooled human liver microsomes (pHLM).34 pHLM are the most commonly used approach for 
metabolism studies as they contain both the primary drug-metabolising cytochrome enzymes and 
the primary conjugation enzymes UDP-glucuronosyltransferases (UGT).35 However, HLM fractions 
lack some enzymes such as N-acetyltransferases and glutathione-S-transferase, which restricts the 
metabolic pathways that can be studied.36  
The pS9 fraction is a sub-cellular fraction prepared from collecting the supernatant of a centrifuged 
tissue homogenate. This contains both pHLC and pHLM and as such can provide simultaneous 
investigation of both phase I metabolites and phase II metabolites, which are mediated by non-CYP 
enzymes.35 However, methods using sub-cellular fractions often require the addition of cofactors 
that mediate oxidative metabolism (i.e. NADPH) or conjugation reactions (i.e. Uridine diphosphate 
glucuronic acid, S-adenosylmethionine), which are lost during the isolation process.35 As these 
cofactors are necessary to catalyse enzymatic reactions the inclusion or exclusion of specific 
cofactors may highlight the involvement of specific metabolism pathways. The cytosol is an isolated 
supernatant of the pS9 fraction which contains a group of drug-metabolizing enzymes and thus can 
be used for investigating specific routes of metabolism. Cytosol incubations are the simplest system 
of the three addressed methods and tend to be used to complement other microsomal based 
studies.35 Recently, primary human hepatocytes (PHH) have been used for investigating both phase I 
and phase II metabolites. PHH cultures are considered the most suitable approach for studying drug 
metabolism as they contain cofactors, metabolism enzymes and drug transporters that closely mimic 
in vivo conditions.37 
In vivo drug metabolism studies include the analysis of metabolites in blood, tissues, and urine to 
assess unique human metabolites.38 In vivo animal or human models offer a method of analysis that 
provides insight of the combined effect of permeability, distribution, metabolism, and excretion and 
hence yield a greater understanding of drug pharmacokinetics.23, 38 The current trend for in vivo 
animal studies is the use of rats to study the metabolism of drugs of abuse. However, interspecies 
variation between the metabolic processes between humans and animals can result in differences in 
the metabolites formed.38 As such, in vitro assays in combination with samples taken from forensic 
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casework are used to collect metabolic profiling data with controlled animal studies treated as 
secondary information.34 
 
1.5 Overview of phase I and phase II metabolism  
 
Knowledge of the phase I and phase II metabolism of cathinone derivatives is crucial for developing  
both screening identification methods and toxicological risk assessments of these compounds.23 The 
behaviour of foreign substances within the body can be divided into four main phases; absorption, 
distribution, metabolism and excretion.39 The absorption of compounds into the body typically 
involves the dissolution of a lipid soluble substance into the lipid membrane via passive diffusion.40 
The route of absorption will depend on the site of administration and the physiochemical 
characteristics of the molecules, particularly relating to their size, shape, lipid solubility, and 
polarity.41 Following absorption, substances will be distributed around the body via either the 
bloodstream or the lymphatic system. Distribution depends on the ability of the molecules to pass 
through the plasma membranes to the extracellular fluid by passive diffusion, active transport or 
facilitated diffusion.42  While some compounds absorbed into the body are eliminated intact, drugs 
that are well absorbed are generally lipophilic and require biotransformation or metabolism into 
water-soluble molecules to facilitate their excretion from the body.40, 41  
 
Drug metabolism within a biological system can be divided into two phases.41 Phase I metabolism 
consists of functionalization reactions which introduce or reveal functional groups to a structure 
such as hydrogen (–OH), amine (-NH2), thiol (-SH) or carboxylic acid (–COOH). These introduced 
groups often act as the site of further conjugation reactions which occur in phase II metabolism 
(Figure 6).39 A number of reactions are responsible for phase I metabolism, the most common of 
which include oxidation, reduction and hydrolysis reactions. In humans, phase I reactions are 
catalysed by several bio-transforming enzymes primarily belonging to the cytochrome p-450 
monooxygenase system; a collection of isoenzymes located primarily in the small endoplasmic 
reticulum (microsomal fraction) and liver cells.40 While majority of compounds will undergo some 
phase I metabolism prior to phase II some compounds which already contain an appropriate 
functional group can undergo phase II conjugation reactions independently of phase I reactions.43  
Phase II metabolism consists of conjugation reactions that introduce an endogenous water-soluble 
group to a molecule at the functional groups previously introduced during phase I. Conjugation 
reactions typically render a molecule lipid soluble (less hydrophilic) and more polar and increases 
the molecular weight of the molecule. As a result, the membrane permeability of the molecule is 
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Figure 6: A schematic of the major pathways of drug biotransformation. 40 
lower, which facilitates excretion from the body (Figure 6).41 The most common phase II reactions 
include glucuronidation, sulphation, and glutathione conjugation reactions. Glucuronidation is a 
process in which a glucuronide moiety is attached to a substrate to produce negatively charged 
hydrophilic glucuronides that can exit the cell via efflux transporters.44 Sulphation involves the 
transfer of a sulfonate group to a substrate containing a hydroxyl or amino group (i.e. the introduced 
functional group) in a reaction catalysed by human cytosolic sulfotransferases (SULTs). Similar to 
glucuronidation this results in possible inactivation of the substrate compound and increased water 
















Natural cathinone metabolises by two main pathways involving reduction and oxidation reactions. 
Cathinone undergoes reduction of the β-keto group to an alcohol to give norpseudoephedrine 
(cathine) and norephedrine (Figure 7).10 This metabolism has previously been shown to be 
stereoselective with the primary metabolite of the S-(−)-cathinone stereoisomer being 
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Figure 7: Schematic representation of the phase I 
metabolism of cathinone. 46 
norephedrine, while the R-(+)-cathinone stereoisomer is primarily metabolised to R,R-(−)- 
norpseudoephedrine.12 Cathinone can also undergo oxidation reactions to give 1-phenyl-1,2-
propanedione or alternatively it can undergo dimerization followed by oxidation to produce 3,6-
dimethyl-2,5-diphenylpyrazine.12 However, in the human body cathinone is metabolised primarily to 
norephedrine.14, 46 
 
As previously eluded to, the lipophilicity of the compound is the major factor that affects the 
absorption, distribution, metabolism and excretion of foreign compounds within the body; all of 
which will influence the biological activity of the compound.41 In human metabolism, genetic factors 
which result in non or less functional enzymes may affect the metabolism of a compound resulting in 
different responses to the toxicological reactions of compounds.40 All four phases of drug disposition 
(i.e. absorption, distribution, metabolism and excretion) could be subject to species variation which 
include, the preferred route of metabolism, the extent to which some compounds are metabolised, 






CHAPTER TWO: Discussion         
Characterising the metabolism of synthetic cathinones is crucial for both developing the 
understanding of their pharmacokinetics and for identifying targets that could be used for 
identification. Unique metabolites and an understanding of metabolic pathways can be incorporated 
into analytical approaches for identification and to assist in the development of urine screening 
methods. Over the past decade the metabolic profiles of synthetic cathinone derivatives have been 
documented by several research groups using a number of different methods. Various review 
articles published in recent years have provided a general overview of synthetic cathinones 
particularly focussed on their pharmacokinetics and analytical methods for metabolic profiling.9, 10, 23 
This section will collate the findings of multiple publications to provide an overview of the metabolic 
pathways observed for a number of synthetic cathinones. For practical purposes, the metabolism of 
each of the synthetic cathinone groups will be discussed separately focussing primarily on the most 
well studied derivatives. As metabolism is likely to differ between species this review will primarily 
focus on studies assessing human in vitro and in vivo metabolism.  
 
 
2.1 Metabolism of N-alkylated cathinone derivatives 
 
The majority of compounds grouped as N-alkylated cathinone derivatives contain various alkyl or 
halogen substituents at the ring and side chain positions. Despite structural differences, common 
metabolic reactions and pathways have been identified for compounds within this group. One of the 
most well studied derivatives is mephedrone, the metabolism of which has been studied in rats or 
rat hepatocytes, in human liver microsomes, and using human urine.47-51 Recently, the in vivo human 
metabolism of mephedrone was evaluated using UHPLC coupled to QTOF-MS. This is one of few 
controlled studies in which urine samples were collected from two volunteers four hours after they 
ingested a known quantity (200 mg) of mephedrone.50 Six phase I and four phase II metabolites were 
identified; four of which (M2, M4, M8, M10) had not previously been reported in the literature. The 


















The identified phase I metabolic reactions included N-demethylation, reduction of the β-ketone 
moiety, oxidation of both the C3 carbon and the aromatic ring, and hydroxylations in the C3 
carbon.47, 50, 51 Overall, it has been suggested that mephedrone is metabolised via three main 
pathways. In both rat and human subjects mephedrone primarily undergoes N-demethylation to 
give the primary amine normephedrone (M1, Figure 8).47, 50 This structure is further transformed via 
β-ketone reduction to give 4′-methylnorephedrine (M5). Metabolites resulting from β-ketone 
reduction and N-demethylation have been suggested as the primary metabolites, both in vivo and in 
HLM incubations.51,49 Additionally, oxidation of the tolyl moiety of mephedrone has been observed 




In regards to phase II metabolism, four conjugated metabolites were identified (Figure 8) three of 
which were conjugated with glucuronic acid (M8, M9 and M10). Interestingly, Pozo et al50 was the 
first to identify a conjugate with succinic acid metabolite in human urine (M4, Figure 8).50  Few other 
researchers have investigated the phase II metabolism of mephedrone, however the metabolism of 
other N-alkylated cathinones has been investigated. In an experiment investigating the metabolism 
of 3,4-DMMC, urine samples were analysed both before and after hydrolysis to identify conjugated 
metabolites.52 The amount of 3,4-DMMC and its metabolites in the urine increased with hydrolysis 
suggesting that they were conjugated, likely with glucuronic acid.52  
Similar metabolic pathways involving N-demethylation and β-ketone reduction have been described 
in both in vivo human and HLM studies for other N-alkylated derivatives such as 3,4-DMMC, 
buphedrone, 4-fluoromethcathinone and 4-methylbuphedrone.49, 52, 53 In a comprehensive study 
conducted by Uralets et al.49 the metabolic profiles of 16 synthetic cathinones detected in human 
urine samples were assessed.49 Of the 16 cathinones identified, nine cathinones were classified as N-
alkylated substituents: pentedrone, 4-MEC, flephedrone, buphedrone, mephedrone, ethcathinone, 
DMMC, 4-Methylbuphedrone and N-ethylbuphedrone. Ring alkylated derivatives primarily 
underwent a ketone reduction to give the corresponding alcohol with a subsequent N-dealkylation 
to form N-dealkylated alcohols in similar pathways to that  observed for mephedrone. As such, the 
abundant β-ketone reduced metabolites were proposed as potential markers for parent drug use. 
Interestingly, Uralets et al.49 noted that the parent drugs were less abundant that their metabolites, 
suggesting a high extent of metabolism. However, as samples were collected at unknown stages of 
urinary excretion, with unknown dosage and time of ingestion no determination could be made as to 
the longevity of the identified metabolites.  Additionally, the authors only considered freely excreted 
non-conjugated metabolites and therefore it is possible that other metabolites were present but 
were undetected.  
 
2.2 Metabolism of 3,4-methylenedioxy cathinone derivatives  
 
Methylenedioxy substituted derivatives are characterised by the presence of a 3,4-methylenedioxy 
group at the aromatic ring. The metabolism of some major 3,4-methylenedioxy substituted 
derivatives such as methylone, ethylone, butylone and pentylone have been characterised both in  
vitro and in vivo.36, 49, 54, 55 As these derivatives are structurally similar, it is unsurprising that 
comparable metabolic pathways have been observed. Metabolites resulting from demethylenation 
and O-methylation are the most abundant phase I metabolites observed in human urine and HLM.49, 
54 In addition, keto-reduced and N-dealkylated products have been observed as minor metabolites, 
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suggesting these reactions occur to a lesser extent. The proposed metabolism and metabolites of 
methylone, as detailed in Figure 9, will be used to illustrate the common metabolic pathways of 3,4-
methylenedioxy derivatives. The major metabolic pathway identified involves demethylenation of 
methylone to form the intermediate diydroxymethcathinone (DHMC). Subsequent O-methylation in 
the aromatic ring of DHMC, via catechol-O-methyl transferase, results in the formation of 4’-
hydroxy-3’-methoxymethcathinone (HMMC) demethylenated metabolites (Figure 9). A number of 
studies have indicated that HMMC is the major metabolite detected both in human urine and in 
HLM suggesting it is a key metabolite for screening purposes.36, 54, 55 Other minor metabolites have 
been identified in in vitro HLM incubations including Nor-methylone and Dihydro-methylone (Figure 
9).54 These are the result of minor metabolic pathways, that involve N-dealkylation and the 
reduction of the β-keto moiety that have been proposed to occur to a lesser extent (Figure 9). In a 
study assessing human urine, Uralets et al.49 proposed that the presence of the methylenedioxy 
group may hinder carbonyl reduction as a result of steric hindrance and thus less reduced 






Figure 9: Proposed in vitro and in vivo metabolic pathway for methylone in humans. 
 Image adapted from54 
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The phase I metabolic pathways observed for methylone are common to butylone, ethylone and 
pentylone with the major metabolites observed being the result of demethylation reactions.49, 54-56 
Currently, there is limited knowledge regarding their phase II metabolism however glucuronides 
have been proposed as potential phase II metabolites.  Zaitsu et al.57 investigated the potential 
conjugation pathways for the hydroxylated and β-keto reduced metabolites on the basis of 
enzymatic hydrolysis.57 After hydrolysis, increases in the urinary levels of 4-HMMC and 3-HMMC 
metabolites were observed as well as increases in the levels of unchanged compounds and β-keto 
reduced metabolites. This suggests potential glucuronidation of the alcohol group of these 
compounds that are excreted in the urine.55, 57 However, given the lack of knowledge surrounding 
phase II metabolism further in vitro and in vivo studies on phase II conjugates is required.  
 
2.3 Metabolism of N-Pyrrolidine cathinone derivatives  
 
The major metabolic pathways of the α-pyrrolidine derivatives have been investigated using both in 
vitro and in vivo methodologies.58-61 Given that N-pyrrolidine derivatives possess both the 3,4-
methylenedioxy substituent and pyrrolidine structure the metabolism of these cathinone derivatives 
is more complex than those previously discussed. One of the most extensively studied derivatives of 
this group is α-PVP, the metabolism of which has been studied using in vitro methods with HLM58, 62  
and in vivo using human urine.49, 61, 62 Two major metabolic pathways identified for α-PVP 
metabolism involve reduction and hydroxylation reactions. One pathway involves reduction of the β-
ketone to give alcohol diastereomers (OH-α-PVP), which are subsequently conjugated to their 
respective glucuronide (Figure 10).61 Further hydroxylation and oxidation of the pyrrolidine ring gives 
the respective lactam structure (2”-oxo-α-PVP) (Figure 10, M3). Overall, OH-α-PVP and PVP lactam 
metabolites represent the two major metabolites of α-PVP.58, 61 In a recent toxicological analysis in 
an acute poisoning case, Grapp et al.63 identified un-metabolized α-PVP and its 2”-oxo-α-PVP 
metabolite in human urine, which was suggested as a potential candidate for identification of α-PVP 
in human urine.49, 63  
Recently, Negreira et al.58 identified for the first time a metabolite proposed to be the  result of a 
complex combination of reactions that involve a reduction of the α-PVP, followed by a hydroxylation 
of the pyrrolidine ring, ring opening, and an additional hydroxylation (M2,M5 Figure 10).58 In 
addition, two phase II glucuronide metabolites of M3 were identified (Figure 10) for the first time in 
any in vitro or in vivo study. However, the glucurorindated metabolites of M6, previously identified 
in other human urine studies, were not identified by Negreira et al.58, which could result from 
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differences in the methodologies employed.41 While extensive metabolic pathways for α-PVP have 
been identified for humans, Tyrkko et al.62 noted, in a study on human urine, that the α-PVP was the 
most abundant compound found in all human urine samples assessed. 
 
The major metabolic pathways identified for α-PVP, namely β-ketone reduction, hydroxylation and 
lactam formation, are common to other α-pyrrolidinophenones such as α-PBP, α-PHP and α-PVT. 
Alpha-PBP has been demonstrated to undergo oxidation at the 2”-position of the pyrrolidine ring to 
give 2”-oxo- α-PBP, with 2”-OH- α-PBP as an intermediate, followed by reduction to form OH-α-
PBP.60 Of the 19 metabolites identified of α-PHP identified in human urine, dihydroxy-α-PHP was the 
most abundant metabolite identified; formed by the reduction of the β-ketone group, similar to 
other pyrrolidinophenones.64  In contrast to the other pyrrolidinophenones, α-PVT was hydroxylated 
at both the thiophene ring and at the pyrrolidine ring to form a lactam species.37, 65 Therefore, 
broadly speaking, lactam species and metabolites generated by reduction of the β-ketone group 
could present a possible target for the identification of pyrrolidine substituted cathinone derivatives. 
Figure 10: Proposed metabolic pathway for α-PVP based on metabolites observed in human 
urine and HLM. M1: PVP-amine (N,N-bis-dealkyl-α-PVP), M2: Carboxylic acid (4-((1,3 or 4-Dihydroxy-1-
phenylpentan-2-yl)amino)butanal), M3:PVP-Lactam (2”-oxo-α-PVP), M4:2”-hydroxy-α-PVP, M5: Carboxylic 
acid (1 or 2-Hydroxy-4-((1-oxo-1-phenylpentan-2-yl)amino)butanal) ,M6: 1-hydroxy- α-PVP.  
Image adapted from58 
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Figure 11: A proposed metabolic pathway for PV9 in humans. The prominent pathways are 
denoted by the highlighted arrows. Circled metabolites indicate the major metabolites identified. 
Image adapted from52 
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There has been a recent focus on investigating the metabolism of the newly synthesised α-
pyrrolidine derivatives, which possess longer side chains such as α-POP and 1-phenyl-2-(1-
pyrrolidinyl)-1-heptanone (PV8). It was proposed that the metabolism of these longer chained 
derivatives may differ from that of α-PVP or α-PBP. Shima et al.66 examined the metabolites of PV9 
in human urine using GC-MS and LC-HRMS. Based on the relative intensities of the protonated 
metabolites identified it was suggested that metabolites formed via oxidation (M9 and M10, Figure 
11), were the most abundant PV9 metabolites. Metabolites formed by the reduction of ketone 
groups and oxidation of pyrrolidine rings (M1 and M6, respectively) represented minor metabolites. 
This suggests that the primary metabolic pathway involved oxidation of the alkyl chain at the 
terminal or penultimate carbon atoms (Figure 11), which differs from that observed for the other α-
pyrrolidionphenones.58, 61, 62 However, this pathway has not been established by other studies. In 
addition, a greater number of metabolites were observed with the increased alkyl chain as there is a 
greater opportunity for metabolism.37 Therefore, it was proposed that the length of the alkyl chain 
influenced the metabolism of the PV9 compared with other pyrrolidine derivatives such as α-PVP 
and α-PBP. However, given that there is minimal published research on the metabolism of PV9 











2.4 Metabolism of 3,4-methylenedioxy-N-alkylated cathinone derivatives 
 
The 3,4-methylenedioxy-N-alkylated derivatives are characterised by both an aromatic substituent 
and a pyrrolidine moiety and hence their metabolism differs from that of the previously discussed 
methylenedioxy group. MDPV, one of the most studied derivatives belonging to this group, is 
structurally similar to α-PVP with the addition of a methylenedioxy substitution. The metabolism of 
MDPV has been studied in vitro using human HLM, human cytosol, and S9 cellular fractions as well 
as in human urine studies.30, 49, 58, 59 The major route for MDPV metabolism involves O-demethylation 
of the 4’-methoxy group to produce a catechol group, namely 3,4 dihydroxy-pyrovalerone (3,4-
catechol-PV). Subsequent O-methylation at the 3’ position of 3,4-catechol-PV gives 4-hydroxy-3-
methoxy-pyrovalerone (4-OH-3-meO-PV).30, 58, 59 In addition to O-demethylation, Negreira et al.58 
observed metabolites that indicated other minor metabolic pathways for MDPV in vitro. MDPV can 
undergo hydroxylation reactions at the pyrrolidine ring and side chain followed by O-demethylation 
and dehydration. Additional hydroxylation of the pyrrolidine ring and oxidation causes opening of 
the pyrrolidine ring, similar to that observed for methylenedioxy substituted derivatives, to produce 
the corresponding aldehyde group (M10, Figure 12).  
In regards to phase II metabolites, both glucuronidated conjugates and sulphated conjugates were 
identified for M2, M3 and M6 metabolites catalysed by UGTs and SULTs and excreted in the urine.58 
Of the metabolites identified only M2 was sulphated while M2, M3 and M6 were glucuronidated 
mainly at the site of hydroxylations and carboxylations of the pyrrolidinophenones (Figure 12). The 
metabolic pathway observed for MDPV has been demonstrated to be common to other 3’,4’-
methylenedioxy-N-alkylated derivatives. The metabolisms of MDPBP and MDPPP have shown a 
similar pathway of demethylenation, side chain and ring hydroxylation, oxidative degradation of 






Figure 12: The proposed metabolic pathway for MDPV in humans. Image 
adapted from58 
  
2.5 Summary of synthetic cathinone metabolism 
 
It has been demonstrated that synthetic cathinone derivatives undergo extensive phase I 
metabolism, oxidation, reduction, methylation, N-dealkylation, and hydroxylation reactions. The 3,4-
methylenedioxy substituted cathinones are primarily metabolized by demethylation reactions; 
however N-dealkylation, O-methylation and reduction of the β-ketone have also been observed. For 
pyrrolidinyl substituted derivatives the major metabolites identified were the products of reduction 
and hydroxylation/oxidation reactions. For derivatives with the presence of a methyl group on the 
phenyl ring, hydroxylation and subsequent oxidation to a carboxylic acid was observed. Multiple 
biotransformation reactions can occur at the pyrrolidine ring structure, the primary reaction being 
hydroxylation of the pyrrolidine ring and dehydrogenation to give a lactam structure. 
Glucuronidation and sulphation were the primary phase II reactions observed for the majority of 
synthetic cathinones, however there has been considerably less research on phase II metabolic 
pathways and thus further research addressing phase II metabolism is crucial; particularly for 




CHAPTER THREE: Cathinone fragmentation patterns    
 
Knowledge of fragmentation pathways is essential for both the identification and structural 
characterisation of synthetic cathinones. As some synthetic cathinones are produced by only small 
modifications in their chemical structure the resultant derivatives possess shared structural 
moieties. As a result, some derivatives can show similar fragmentation pathways and common 
fragment ions. Determination of common fragmentation pathways could assist in the detection and 
identification of cathinone derivatives and assist researchers to predict the formation of fragment 
ions for derivatives of similar structure. A number of articles have been published that have 
illustrated the fragmentation pathways for selected cathinone derivatives.69-75 Majority of these 
publications used high resolution methods that incorporated electrospray ionisation and CID to 
assist in structural elucidation. This section will provide an overview of the current knowledge of the 
fragmentation pathways of synthetic cathinones focussing on a number of key publications that 
have assessed general fragmentation pathways. 
 
 
3.1 General fragmentation patterns of synthetic cathinones 
 
The fragmentation patterns of synthetic cathinones are considered to be characterised by the 
molecule side-chain; with the base peak of the spectra largely dependent on the number of carbon 
atoms substituted at the R3, R4 and R5 position. As such, different cathinone derivatives with similar 
side chains (i.e. those with identical number of carbon atoms in R3 and R5 positions) can produce 
base peaks with identical m/z values.71 Cathinone compounds that fall into the same class have been 
shown to fragment via similar pathways with some common primary product ions.69 To establish the 
general fragmentation pathways of synthetic cathinones, Fornal69 investigated the CID 
fragmentation pathways of 39 protonated cathinone derivatives using reverse-phase HPLC coupled 
Q-TOF-MS equipped with a collision cell for ion fragmentation. Based on their chemical structure 
each of the assessed cathinones was divided into six classes and the fragmentation patterns of each 
were investigated (Table 1). Overall four general fragmentation pathways were identified for the 









































Table 1: Summary of the names, formulae and structures of the 39 investigated cathinone 
derivatives. Substituents: methyl (CH3); Et, ethyl (C2H5); Pr, propyl (C3H7); MeOx, methoxy (CH3O); 
Pyr, pyrrolidinyl (C4H8NH); DMe, dimethyl (two CH3); MeDOx, methylenedioxy (–O–CH2–O). 69 
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The loss of water (Pathway 1) resulted in the formation of the highly abundant dehydrated [M-
H2O+H]
+ ion which is characterised by a loss of 18.01060 Da (H2O) from the precursor  molecular ion 
(Figure 13).69, 70, 73 The loss of water is proposed to occur as a result of the affinity of the carbonyl’s 
oxygen for the hydrogen on the α-carbon, which results in a  hydrogen shift form the amine to the 
protonated oxygen of the ketone.73 As this hydrogen shift requires physical proximity between the 
amine and the oxygen, longer carbon chains between these structure have been suggested to limit 
the migration of hydrogen and hence the loss of water.76 Therefore, the loss of water is mostly 
expected for cathinone derivatives in which the amine group is a primary or secondary amine that 
possesses at least one hydrogen atom.69, 76 It was noted that the water loss was most abundant for 
classes IA and IIIA, which are comprised mainly of primary aliphatic amines and methylenedioxy 
substituted primary aliphatic amines. No water loss (i.e. an absence of [M-H2O+H]
+ ions) was noted 
for classes IIIB, IV and V (Table 1).  
 
The second common fragmentation pathway identified was the cleavage of the CH-NR3R4 bond 
(Pathway 2) resulting in the loss of an amine (NHR3R4) and production of a [NR3R4+H]
+ ion (Figure 13). 
This pathway was proposed to be characteristic to all cathinones (with the exception of BMDP); 
however, the highest abundance of the characteristic [NR3R4+H]
+ ion was observed for classes IB, II, 
IIIB, IV and VA (Table 1).69 The introduction of different R1 and R2 substitutions influenced the 
proportion of [NR3R4+H]
+ ions detected for specific cathinones. The introduction of a 4-methyl 
substituent at the phenyl ring of the structure (i.e. mephedrone, methedrone, MPPP etc.) was 
associated with an increase in the formation of [NR3R4+H]
+ ions, while the introduction of a methoxy 
substituent at the same position was associated with a decrease in the intensity of [NR3R4+H]
+ ion 
formation.69 For compounds with the same R1 substituent (i.e. 4-me, 4-meox, 3,4-mediox) the 
abundance of ion formation showed dependence on the length of the R2 substituent such that 






Figure 13: A schematic representation of the postulated general CID fragmentation 
pathways of synthetic cathinones. 69 
 
A key feature of the fragmentation of cathinone derivatives was the formation of an immonium 
cation [R2CH2CH=NR3R4]
+ as a result of the cleavage of the CO-CHCH2R2 bond (Pathway 3a). The 
formation of immonium cations was observed for all cathinone derivatives assessed, which is in 
agreement with previous publications.70, 74 The cumulative relative intensity of immonium ions in the 
spectra was highest for cathinones belonging to classes IIIB and IV, while the abundance was 
comparatively for those cathinones belonging to classes IIA and VA (Table 1). Additionally it was 
noted that immonium cations were generated at higher collision energies (20 eV and 40 eV) unlike 
the other observed ions ([NR3R4+H]
+ and [M-H2O+H]
+), which were observed at lower collision 
energies.69 A secondary pathway (Pathway 3b) was identified that involved the formation of an 
oxonium ion and the loss of an amine R2(CH2)2NR3R4 (Figure 13).  However, a low abundance of this 
ion was observed across all six cathinone classes, suggesting it is not a favourable pathway. The final 
pathway identified (Pathway 4) was the loss of CH4O2 (48.0211Da), which is attributed to the 
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methylenedioxy group (Figure 13). This pathway was common to cathinones of classes IIIA and VI 
(both methylenedioxy substituted derivatives).  
 
The fragmentation of 3,4-methylenedioxy substituted derivatives has been studied in detail in a 
separate study by Fornal70 in which LC-ESI-Q/TOF was used to investigate the CID fragmentation 
pathways of methylone, butylone, pentylone, MDPBP, MDPV and BMDP. The major pathway 
observed was loss of CH4O2 from the methylenedioxy group, that was accompanied by the formation 
of phenyloxazole cations (Cation B, Figure 14).69, 70, 73 Additionally the formation of 
methylenedioxybenzoyloxonium ions (Cation D), allyldioxybenzoyloxonium ions (cation C), and 
immonium ions (Cation E) was also observed for 3,4-methylenedioxy substituted derivatives (Figure 
14).70 Interestingly, the assessed MDPV and MDPBP compounds, both of which contain a pyrrolidinyl 
group had different fragmentation mechanisms compared to the other compounds assessed. 
Neither fragment ion A nor fragment ion B were observed for these compounds at any assessed 
collision level.  This was proposed to be the result of steric hindrance from the pyrrolidinyl moiety, 
which prevents the removal of the CH4O2.
70 This observation is consistent with the findings of 




Figure 14: A postulated fragmentation pattern of 3,4-methylenedioxy substituted cathinone 
derivatives.  (a) Fragment formation inhibited for MDPBP and (b) Fragment formation inhibited 
for BMPP. 70 
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3.2 Fragmentation patterns for N-pyrrolidinyl substituted cathinone 
derivatives 
 
To investigate the generalised fragmentation routes of pyrrolidinyl substituted derivatives 13 
substituted cathinones of varying alkyl chain length (ranging from one to seven carbons) and various 
aromatic ring substituents (i.e. H, Cl, F, CH3, OCH, O(CH2)2 to (CH2)4) were selected.
72 The two major 
fragmentation routes observed for pyrrolidinyl substituted derivatives were: the cleavage of the CH-
N(CH2)4 bond resulting in the loss of an  amine moiety, and cleavage of the CO-CHN bond.
72 The loss 
of the amine resulted in the formation of product ion A (Figure 15); which is suggested to be 
characteristic of all pyrrolidinyl substituted derivatives. Further dissociation of CO and the alkyl chain 
from product ion A was suggested to result in the production of product ion C (Figure 15), another 
highly abundant ion in the spectra of most of the assessed cathinones.72 However, for the formation 
of product ion B and C an alkyl substitution (R2 substitution) of at least two carbon atoms was 
required. Cleavage of the CO-CHN bond resulted in the formation of benzoyl ions (ion D) and 
immonium cations (Ion G); similar to that observed by Fornal69 (Figure 15). Lastly, loss of the alky 
chain from the protonated molecule was observed for most of the pyrrolidinyl substituted 
cathinones which resulted in the formation of radical ion F (Figure 15). However, this ion was 
observed at a relatively low intensity especially with the introduction of O(CH2)2 or (CH2)4 






































3.3 Summary of fragmentation 
 
The literature has demonstrated a degree of predictability within the fragmentation of synthetic 
cathinones. Synthetic cathinones that belong to the same group (as denoted by their chemical 
structure) fragment via similar pathways, producing characteristic fragment ions that can be used to 
assist in the classification of cathinone derivatives. The generalised fragmentation pathways 
described in this review can be treated as a framework to assist in the categorisation of unknown 
compounds into a specific group of cathinones.  These fragmentation pathways could assist in not 
only classifying compounds according to class but could also highlight unique peaks that can be used 
to identify potentially viable structures in the identification of unknown compounds.  
Figure 15: The proposed generalised fragmentation pathways for pyrrolidinyl 
substituted cathinone derivatives. 72 
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CHAPTER FOUR: Conclusion       
 
The aim of this review was to provide a comprehensive and up-to-date overview of the knowledge 
surrounding the metabolism and mass-spectral fragmentation of synthetic cathinones.  A major 
problem in the analysis of synthetic cathinones is that a large number of them are structurally 
similar, which makes identification difficult; especially in consideration of the lack of reference 
standards for newly synthesised synthetic cathinones. While a substantial amount of information is 
known about the metabolism of synthetic cathinones, a considerable number of cathinone 
metabolites have yet to be characterised. Further studies are therefore necessary to not only 
establish the metabolic profiles of newly synthesised cathinone derivatives, but to also incorporate 
the identified metabolites into identification and quantification methods. While a number of 
publications have proposed potential metabolites to be used as detection markers, there is a lack of 
validation studies to confirm the consistent presence of such metabolites in a range of biological 
matrices. Another limitation of the current knowledge of the metabolism of synthetic cathinones 
stems from a lack of controlled studies in humans. Studies using human urine were often performed 
using samples with unknown dosage amount, time of ingestion, and with samples collected at 
unknown urinary phases; each of which has an impact on the metabolites observed.  
 
Knowledge of mass spectral fragmentation patterns is a crucial tool for the identification of synthetic 
cathinone structures. This review focussed on the characteristic fragmentation patterns identified 
for cathinone derivatives using high-resolution LC-ESI/QTOF-MS techniques. While an abundance of 
information regarding CID fragmentation pathways currently exists, most of the information is 
scattered across a number of publications; many of which focus on the identification of an individual 
cathinone. While the publications discussed in this review have attempted to collate this information 
by establishing generic fragmentation pathways, further evaluation and examination of the 
literature would be beneficial to produce a consolidated resource that summarises the 
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The emergence and propagation of synthetic cathinones on the designer drug market is an evolving 
worldwide problem. Synthetic cathinones encompass a diverse range of compounds with varying 
structural features and substituted functional groups. This variability, in combination with their 
widespread availability, poses a challenge for forensic and toxicology laboratories to develop and 
maintain analytical methods for the detection and identification of synthetic cathinone derivatives 
and their associated metabolites. The aim of this dissertation was to consolidate the current 
knowledge regarding the metabolism and the collision induced dissociation spectral fragmentation 
of synthetic cathinone derivatives. This will involve the collation and discussion of the m/z values 
observed for characteristic fragment ions of each class of cathinone derivative, in addition to some 
characteristic higher-order fragment ions; with the objective of developing a combined resource 
from which general conclusions regarding the fragmentation patterns of synthetic cathinones can be 
drawn.  The main fragmentation pathways for cathinone derivatives and the primary CID fragment 
ions could assist in the identification of newly-synthesised cathinone derivatives and facilitate the 
development of detection methods for synthetic cathinones.   
 
 
Keywords:  Synthetic cathinones; Metabolism; Cathinone Fragmentation patterns; Novel 







The continual emergence of novel psychoactive substances (NPS), also known as “designer drugs” or 
“legal highs” is a growing worldwide problem. NPS constitute an evolving mixture of modified 
substances that are designed to reproduce the effects of other illicit substances such as cannabis, 
hallucinogens and stimulants.1 Synthetic cathinones constitute a class of NPS that has experienced 
an increased emergence on the drug market over the last decade. A report published by the 
Australian Criminal Intelligence Commission suggested that cathinone-type substances accounted 
for 33.3% of analysed seizure samples between 2015 and 2016, which is in line with the trends  
observed in European countries.2, 3 Synthetic cathinones are derivatives or analogues of the β-keto 
amphetamine cathinone; the major psychoactive stimulant component of the psychoactive plant 
Catha Edulis or Khat.4 These derivatives possess numerous structural modifications and substitutions 
creating a diverse range of compounds. Synthetic cathinones are primarily marketed and sold 
through online networks; often in packaging with minimal composition information.5 Therefore, 
analytical approaches for the detection and identification of these compounds are crucial to 
ascertain the structure of new cathinone compounds and to assist in toxicological risk assessment. 
However, the structural diversity of cathinone derivatives available on the drug market and the lack 
of available reference standards or database libraries poses a challenge for forensic laboratories to 
develop and maintain analytical methods for the detection of these substances and their 
metabolites.6 
Various spectrometric techniques have been employed to assist in the identification and structural 
characterisation of synthetic cathinone compounds.7 Spectrometric methods such as gas-
chromatography mass spectrometry (GC-MS) and liquid-chromatography mass spectrometry (LC-
MS), coupled to high resolution mass spectrometry (HRMS) are commonly published methodologies 
for the identification and structural characterisation of synthetic cathinones.8 The incorporation of 
collision induced dissociation (CID) fragmentation with a high resolution mass spectrometer can 
provide crucial information regarding both the composition of the molecule, and in identifying the 
fragmentation pathways and the primary metabolites of specific synthetic cathinones. Furthermore, 
HRMS methods can be useful for the identification of compounds without the need for reference 
standards; which are often unavailable for newly synthesised synthetic cathinones.9 While an 
abundance of information regarding the fragmentation of synthetic cathinones exists, the 
information is often scattered across multiple publications; the majority of which focus on the 
structural characterisation of an individual derivative or a few selected cathinone derivatives. As 
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such there is a lack of consolidated information that compares the similarities and differences of the 
pathways observed within the literature for specific cathinone derivatives.  
The aim of this dissertation is to provide a comprehensive review of the mass spectral fragmentation 
characteristics of synthetic cathinone derivatives and the metabolism of these substances. This will 
involve comparing the published data, specifically the mass-to-charge ratio (m/z) values observed 
throughout the literature for specific cathinone fragment ions with the objective of producing a 
consolidated resource. A review of the literature was conducted, focussing on literature that 
discussed the characterisation of mass-spectral fragmentation pathways of cathinone derivatives, 
the identification of metabolic pathways, and identification of metabolites.  
 
2.0 Structure and chemistry of synthetic cathinones  
  
Synthetic cathinone derivatives possess the common structure of the natural compound cathinone. 
The structure of cathinone closely resembles that of amphetamine, which is differentiated by the 
presence of a ketone functional group at the β-amino chain attached to the phenyl ring (Figure 1).10 
Given this structural similarity, cathinone and its synthetic derivatives produce effects similar to 
those of amphetamines such as central nervous system effects, including increased sensory 
stimulation, euphoria, excitation, and agitation.11 Synthetic cathinones are primarily available in 
crystalline and powder forms that can be administered by snorting, smoking, oral ingestion, and less 






Figure 1: Comparison of the natural cathinone structure (Left) and the amphetamine 
structure (Right). Source: Kelly11 
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The natural structure of cathinone lends itself easily to modifications at several locations on the 
molecule. The addition of various substitutions on the cathinone molecule results in the generation 
of a large number of synthetic cathinone derivatives that can be classified based on their chemical 
structures.4 Synthetic cathinones are formed by either ring substitution at the R1 position, variation 
in the α-carbon substituent (R2), or N-alkylation at the R3 and R4 positions (Table 1).
10  Based on these 
substitutions, synthetic cathinones can be categorised into four chemical families: N-alkylated 
derivatives, methylenedioxy-substituted derivatives, N-pyrrolidine derivatives, and 3,4-
methylenedioxy-N-pyrrolidine derivatives.4 Table 1 displays a list of the N-alkylated and 
methylenedioxy synthetic cathinones arranged by their chemical substituents at each of the 
substitution points.10 Table 2 represents the chemical and substituents of the pyrrolidine substituted 



















Table 1: The chemical structures of the N-alkylated and methylenedioxy substituted 
cathinone derivatives.  3,4-DMMC, 3,4-dimethyl-methcathinone; 4-MEC, 4-
methylcathinone; DMMC,  Dimethylmethcathinone; BMDP, 3,4-methylenedioxy-N-benzyl 
cathinone. 
 




The N-alkylated cathinones are a group of derivatives characterised by the presence of substituents 
at the R3 and R4 sites, and/or compounds with an alkyl or halogen substituent at the R1 position 
(Table 1). The methylenedioxy cathinone derivatives are characterised by the addition of a 
methylenedioxy substituent at the aromatic ring (R1) (Table 1). Pyrrolidinyl cathinone derivatives are 
characterised by the presence of a pyrrolidine ring at the nitrogen, instead of an amine or N-methyl 
amine substitute (Table 2). The 3,4-methylenedioxy-N-pyrrolidine cathinone derivatives are 
characterised by the presence of both a methylenedioxy substitution at the R1 position and the 
presence of a pyrrolidinyl substituent at the nitrogen atom (Table 2). Similarity between the 
chemical structures of synthetic cathinones, in addition to their increasing numbers, poses an 
analytical challenge for the detection and identification of specific cathinones, particularly if the 
analytical technique used does not provide any information relating to the parent compound.   
 
Table 2: The chemical structures of pyrrolidinyl substituted cathinone derivatives.  α-PPP, α-
pyrrolidinopropiophenone; α-PHP, α-pyrrolidinohexanophenone ;α-PVP,α-pyrrolidinovalerophenone; α-PBP, α-
pyrrolidinobutyrophenone; α-PEP, α-pyrrolidinoenanthophenone;  α-; α-POP, α-pyrrolidinooctanophenone; 
MPPP, 4-methyl-α-pyrrolidinopropiophenone; MOPPP, 4-methoxy-α-pyrrolidinopropiophenone; MPBP, 4'-
Methyl-α-pyrrolidinobutiophenone; MDPPP, 3,4-methylenedioxy-α-pyrrolidinopropiophenone ; MDPBP,3,4-
methylenedioxy-α-pyrrolidinobutiophenone; MDPV, 3,4-methylenedioxypyrolvalerone. 
 
Substituents: CH3, methyl; C2H5, ethyl; C3H7, propyl; OCH3, methoxy. 
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3.0 Metabolism of synthetic cathinones 
 
Characterisation of both the in vivo and in vitro synthetic cathinone metabolites is important for 
identifying unique metabolite targets that can be incorporated into analytical approaches for the 
identification of compounds and in the development of urine screening methods.13  
3.1 N-alkylated cathinone derivatives  
 
Primary metabolic pathways of N-dealkylation and β-ketone reduction have been described in both 
in vivo human urine and HLM studies for N-alkylated cathinone derivatives.14, 15 A recent 
comprehensive study conducted by Uralets et al.16, summarised the metabolic profiles of 16 
synthetic cathinones that were detected in human urine samples. Nine of the cathinones identified 
were classified as N-alkylated substituents, which included: pentedrone, 4-MEC, flephedrone, 
buphedrone, mephedrone, ethcathinone, DMMC, 4-Methylbuphedrone and N-ethylbuphedrone. 
These derivatives were proposed to be metabolised via N-dealkylation and ketone reduction to give 
the corresponding alcohol; with subsequent N-dealkylation resulting in N-dealkylated alcohol 
metabolites (Figure 2).16-18  
For those cathinone derivatives with a 4-methyl group hydroxylation and carboxylation of the 4-
methyl group was observed, while those with a 4-methoxy-substitution (i.e. methedrone) O-
demethylation is a commonly observed metabolic pathway in vitro.15, 19, 20 Uralets et al.16 noted that 
the parent drugs were less abundant than their metabolites, suggesting a high extent of metabolism. 
However, urine samples were collected at unknown stages of urinary excretion, with unknown 
dosage and time of ingestion and therefore no determination can be made about the longevity of 
the metabolites. Additionally, the authors only considered freely excreted non-conjugated 
metabolites and therefore it is possible that other metabolites were present but were undetected. In 
regards to phase II metabolism, glucuronic conjugates have been identified both in vitro and in 
human urine.21 In a study investigating mephedrone, Pozo et al.15 identified glucuronide conjugates 
within human urine samples.  In addition, Pozo et al.15 was the first to identify a conjugate with 









3.2 Pyrrolidine-substituted cathinone derivatives 
 
The metabolism of selected pyrrolidine substituted cathinone derivatives has been studied 
extensively using both in vitro methodologies using pS9, pooled human liver microsomes (pHLM) 
and liver cytosol, and within human urine samples.17, 18, 20, 22-24 The metabolic pathways of pyrrolidine 
derivatives primarily involve the reduction of the ketone group to the corresponding alcohol, 
hydroxylation of the pyrrolidine ring to generate a corresponding pyrrolidone, and hydroxylation of 
the aliphatic side chain (Figure 3).20  Recently, Manier et al.13 examined the in vitro metabolism of 
the pyrrolidine derivatives α-PBP, α-PVP, α-PHP, α-PEP, and α-POP using PS9 and pHLM incubations. 
All of the assessed compounds were shown to undergo hydroxylation reactions and the formation of 
lactam groups (Figure 3); findings that are consistent with other publications assessing in vitro 
metabolism of α-pyrrolidinophenones.18, 20 The majority of compounds such as α-PBP, α-PHP, α-PEP, 
and α-POP are hydroxylated at the pyrrolidine ring, resulting in the formation of mono- and 
dihydroxy metabolites. Interestingly, α-PBP undergoes hydroxylation solely at the pyrrolidine ring 
while α-PHP, α-PEP, and α-POP have shown additional hydroxylation at the alkyl chain and mono 
Figure 2: The proposed metabolic pathway of mephedrone in humans. Image adapted from 
Pozo et al.15.  
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and bis-hydroxylation.13 In contrast to other α-pyrrolidinophenones, α-PVT undergoes hydroxylation 
reactions at both the thiophene ring and the pyrrolidine ring to form mono- and dihydroxy 
metabolites.25 Additional hydroxylation at the aliphatic side chain of α-PEP and α-POP has also been 
observed to produce oxo and carboxy metabolites respectively.13 Shima et al.17 proposed that the 
main metabolic pathways of pyrrolidine cathinone derivatives will differ markedly based on the 
length of the alkyl chain. For compounds with longer chains such as α-POP and α-PV8 (Table 2), 
metabolites formed by oxidation reactions have been proposed as the primary metabolites for PV9, 
while metabolites formed via hydroxylation or reduction of the ketone group represent minor 







Figure 3: Proposed metabolic pathway for α-PVP based on metabolites observed in human 




3.3 Methylenedioxy substituted cathinone derivatives 
 
Methylenedioxy cathinones such as methylone, butylone, ethylone, and pentylone have been 
characterised both in vitro and in vivo.16, 19, 26, 27 As these derivatives are structurally similar, it is 
unsurprising that comparable metabolic pathways have been observed. These compounds primarily 
undergo demethylenation reactions both in vitro and in vivo; with metabolites resulting from 
demethylenation and O-demethylenation among the most common metabolites identified (Figure 
4). Additionally, the N-dealkylation and β-ketone reduction reactions have also been observed for 
the methylenedioxy substituted derivatives at a lesser extent than was observed for N-alkylated 
cathinone derivatives.16 This may be a consequence of steric restrictions resulting from the presence 







Figure 4: Proposed in vitro and in vivo metabolic pathway for methylone in humans. 
 Image adapted from Pedersen et al. 26  
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4.0 Proposed fragmentation patterns of cathinone derivatives 
 
An understanding of the CID fragmentation pathways for synthetic cathinones is crucial for both the 
identification and structural characterisation of synthetic cathinones and unknown metabolites. The 
fragmentation patterns of numerous synthetic cathinones have been investigated by several 
research groups; producing an abundance of published research.29-34 The fragmentation of synthetic 
cathinones is considered to be dependent on the functional group attached to the molecule side 
chain, and the number of carbon atoms substituted at the R3, R4, and R5 positions. As such, 
compounds with a similar structure have been suggested to fragment via similar fragmentation 
pathways and produce common fragment ions.32 The cleavage of functional groups from the 
chemical structure is associated with the production of distinct peaks on a resultant mass spectrum; 
the m/z values of which differ based on the absence or presence of substituents. Therefore, 
different fragmentation patterns for synthetic cathinones can be anticipated based on the chemical 
structure of the compound, and can be used to differentiate between compounds.  
General CID fragmentation pathways that apply to a range of cathinone derivatives have been 
explored in a number of publications.29, 30, 33 Fornal29 investigated the CID fragmentation patterns 
and primary product ions of 39 synthetic cathinone derivatives using quadruple time-of-flight mass 
spectrometry (Q-TOF) with electrospray ionisation and CID. Four main dissociation pathways have 
been observed across a range of synthetic cathinone derivatives. The primary product ions identified 
are the result of the loss of water, the loss of an amine, production of an immonium ion, production 
of an oxonium ion, and the loss of the CH4O2 moiety (Figure 5).
29 The elimination of H2O from the 
protonated molecule results in the production of a [H2O+H]+ ion which is characterised by a loss of 
18.01060Da (H2O) from the precursor molecular ion (Figure 5, Pathway 1). The cleavage of the CH-
NR3R4 bond results in the loss of an amine (NHR3R4) producing [NR3R4H]
+ ions (Figure 5, pathway 2). 
Cleavage of the CO-CHCH2R2 bond results in the production of immonium ions, the m/z value of 
which will depend on the R2, R3 and R4 substituents. The production of immonium ions is dominant 
in most cathinones suggesting this as a major fragmentation pathway. A secondary pathway that 
involves the formation of an oxonium ion (R2(CH2)2NR3R4) has also been observed (Figure 5, pathway 
3B); however these ions have been observed at low abundance indicating it is not a primary 
fragmentation pathway.29 The final generalised fragmentation pathway is ascribed to the loss of a 






















Each of these major fragmentation pathways results in the formation of distinct fragment ions, the 
m/z values of which will differ depending on the different functional group substitutions. However, 
the formation of some of these fragment ions (i.e. immonium cations or [M-CH4O2]
+ ions) are not 
unique to cathinone derivatives. For instance, cations formed from the loss of the amine are also 




Figure 5: A schematic representation of the postulated CID fragmentation pathways for 




5.0 Summary of the observed m/z values for fragment ions of 
synthetic cathinone derivatives.  
 
The published m/z data of primary fragment ions obtained from multiple publications will be 
collated and compared. To allow comparisons between articles the mass spectral m/z values 
compared were generated using comparable methodologies. In each of the selected articles the 
mass-spectral fragmentation of the selected cathinone derivatives were investigated using high-
performance-liquid-chromatography quadruple time-of-flight-mass spectrometry (HPLC-QTOF-MS) 
following collision induced dissociation and electrospray ionisation techniques.29-31, 33 The discussed 
fragment ions were generated using fixed collision energies at 10, 20 and 40 eV; with the exception 
of Qian et al.33 where the mass spectra were acquired at sweeping collision energies set at 35±45 eV. 
 
5.1 Fragmentation patterns of N-alkylated cathinone derivatives 
 
The characteristic fragment ions listed and described in Table 3 suggest that the majority of N-
alkylated cathinone compounds primarily yield dehydrogenated ions, ions resulting from the loss of 
amine, and immonium cations. Of the range of fragment ions identified in the collected data, 
Fornal29 suggested that the formation of the [M-H2O + H]
+ ions were among the most abundant 
identified for the N-alkylated class of cathinones. In addition, Fornal29 proposed that the cumulative 
relative intensity of these ions increased in proportion to the length of the R1 substituent. The loss of 
water is proposed to result from a hydrogen shift from the α-carbon to the protonated oxygen of the 
ketone; a shift that requires physical proximity between the amine and the oxygen.34 Therefore, 
longer carbon chains between these structures have been suggested to limit the migration of 
hydrogen and, as such, the loss of water from molecules has been proposed to be indicative of 
cathinone derivatives in which the amine group is a primary or secondary amine that possesses at 
least one hydrogen atom.31 
The m/z values for a number of the discussed fragment ions were similar between different 
cathinone derivatives, indicating that derivatives of similar structure produced similar fragment ions. 
This was specifically observed for fragments formed as a result of amine cleavage [M-NHR3R4+H]
+ 
and immonium cations (Table 3). Three distinct clusters of m/z values could be observed for the [M-
NHR3R4+H]
+  fragment ions with m/z values of approximately 161.0961 (C11H13O), 133.0649 (C9H9O+), 
and 147.0808 (C10H11O) (Table 3). Similarly for the produced immonium cations, m/z values of 
approximately 86.09 and 72.08 were observed across a number of the assessed derivatives. Fornal29 
noted that the relative abundance of immonium ions in the spectra was significantly lower than 
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those of other characteristic product ions.29 However, it is worth noting that the data collated in 
Table 3 are limited to that published in Fornal29 and therefore, in regards to trends in the 
fragmentation, only limited conclusions can be drawn. 
 
5.2 Fragmentation patterns of 3,4-methylenedioxy substituted cathinone 
derivatives 
 
Fragment ions associated with the loss of the neutral group CH4O2 (48.0211) have been proposed as 
the primary fragment ion and fragmentation pathway for methylenedioxy cathinone derivatives.29, 30 
For [M-CH4O2] fragment ions m/z values of 174.0911 (C11H12NO) and 188.1069 (C12H14NO) were 
consistently observed for butylone, ethylone, pentylone and eutylone, respectively (Table 4). Given 
that the loss of the CH4O2 is unique of methylenedioxy substituted cathinones, the observation of 
this fragment ion could be useful to facilitate identification. However, while this fragment ion 
represents a characteristic of methylenedioxy, additional fragments ions have also been identified 
that can identify the structural features of methylenedioxy substituted cathinone derivatives.29, 30 
The fragment ions corresponding to the loss of water, the loss of amine, and immonium ion 
formation, which were observed for the N-alkylated derivatives, have also been observed in 
methylenedioxy substituted cathinone derivatives (Table 4).29, 30  However, Fornal29 noted that these 
were present at lower abundances in methylenedioxy derivatives than was observed for the N-
alkylated derivatives. For N-methyl derivatives at a low collision energy (10 eV), [M-H2O]
+ and [M-
C4H2O]
+ were the most abundant fragment ions observed for these compounds, while at higher 
collision energies (20 eV and 40 eV) the [C9H9N]+/ [C9H10N]+  ions formed from the elimination of 
H20, methanedial and C-alkyl were the most abundant fragment ions observed.
30 Therefore, 
consideration of the collision energies used must be considered during the analysis of mass 
spectrums.  
 
In addition to the discussed general fragment ions, a number of characteristic higher-order product 
ions have been identified for methylenedioxy cathinone derivatives (Ion 5 and Ion 6, Table 4). For 
methylone, butylone, and pentylone characteristic fragment ions with m/z values of 147.0437 
(C9H7O2)
+, m/z 161.0597 (C10H9O2)
+, and m/z 175.0751 (C11H11O2)
+ have been observed, that 
correspond to the loss of formaldehyde and amine (NHR3R4) from the protonated molecular ions.
29 
The emergence of these fragment ions has been proposed to be formed after the loss of water, 




Interestingly, the N-benzyl derivative BMDP (structure shown in Table 1) exhibited a different CID 
fragmentation profile from that observed for the other methylenedioxy substituted cathinone 
derivatives. For BMDP, the most abundant fragment ion observed in the literature was the stable 
tropylium cation (m/z value 91.0542, [C7H7]) (Table 4).
31 It has been proposed that the presence of 
the benzyl group (i.e. a group of atoms capable of forming the tropylium ion) results in a shift in the 
fragmentation to produce immonium ions.30, 31 As such, the BMDP spectra is characterised by a base 
peak of tropylium cations while the other characteristic ions observed for other cathinone 
derivatives are present only at lower collision energies.  
For those compounds which contain both the 3,4-methylenedioxy structure and the pyrrolidine 
moiety (i.e. 3,4-MDPPP, 3,4-MDPBP, MDPV), neither the dehydrogenated ions ([M-H2O]
+) or 
phenyloxazole ions ([M-CH4O2]
+) have been observed (Table 4). It has been proposed that the 
presence of the pyrrolidine structure in these molecules restricts the 1,5 hydrogen shifts from the 
pyrrolidine group to the carbonyl group and hence the elimination of the CH4O2 is impossible.
30 
Similarly, the absence of [M-H2O]
+ ions also suggests that the mobility of the hydrogen on the amino 
group could be restricted. Given that the loss of water has been proposed to involve the migration of 
hydrogen from the amine group, it is suggested that fragment ions resulting from the loss of water 
would not occur, or fragment ions would occur at low abundances when an amine group is a tertiary 
amine.29 
 
5.3 Fragmentation patterns of pyrrolidinyl substituted cathinone 
derivatives 
 
The two major fragmentation routes observed for pyrrolidinyl substituted derivatives are the 
cleavage of the CH-N(CH2)4 bond resulting in the loss of an amine moiety, and cleavage of the CO-
CHN bond.33 Based on the identified fragment ions it can be determined that pyrrolidinyl substituted 
cathinone derivatives undergo elimination of the pyrrolidine ring via α-cleavage of the amine group, 
resulting in the formation of (NHR3R4 +H
+) ions and immonium cations; the m/z values of which differ 
depending on the chemical structure of the compound. The m/z values for the fragment ions 
observed are relatively consistent between each of the articles published, with only minor 
differences observed between values (Table 5). However, in regards to the observation of fragment 
ions resulting from the loss of water, the data published by Manier et al.13 did not report any [M-
H2O]
+ fragment ions, a finding that differs to the data published by both Fornal29  and Qian et al.33.  
Fornal29 observed that the cumulative relative abundance of the immonium ions observed suggested 
that immonium cations represent a primary product ion for pyrrolidine substituted cathinone 
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derivatives. The cumulative relative abundance of the characteristic fragment ions is dependent on 
the collision energies applied. At higher collision energies (i.e. 20 eV and 40 eV) immonium ions are 
the most abundant fragment ions, while at lower collision energies other characteristic fragment 
ions, [NR3R4+H]+ and [M-H2O+H]+, were the most abundant observed.29  
 
Fragment ions between m/z 70.648 and 72.0809 have been observed for all pyrrolidine compounds, 
with the exception of MPBP and MOPPP which showed m/z values of 133.101 and 179.1055 
respectively (Table 5). Manier et al13 proposed that these fragment ions are the result of 
hydroxylation of the pyrrolidine ring that results in the removal of an oxo group from the pyrrolidine 
ring, and the production of a fragment ion (C4H8N). The observation of fragment ions which 
represent the mono and dihydroxy metabolites corresponds to the metabolic pathways and 
metabolites observed in in vitro and in vivo metabolism studies.13, 20 Additional fragmentation ions 
corresponding to the formation of a tropylium ion (m/z 91.0542, [C7H7]) have consistently been 
observed for a number of pyrrolidine cathinone derivatives including α-PBP, α-PVP, α-PHP, α-PEP, 
and α-POP.13, 33 However, variation in the m/z values was observed for the other pyrrolidine 
derivatives assessed with the different structural features, especially relating to the length of the 




While a substantial amount of information is known about the metabolism of synthetic cathinones, a 
considerable number of cathinone metabolites have yet to be characterised. Therefore, further 
research investigating the metabolism of newly-synthesised cathinone derivatives is necessary. 
While a number of metabolites for specific cathinone derivatives have been identified as potential 
markers of parent drug use, further work is required to incorporate the identified metabolites into 
quantification and drug screening methods for detection. The identification of common metabolic 
pathways among synthetic cathinones is crucial particularly for the detection or the characterisation 
of unknown metabolites identified in samples. For instance, in situations in which product ions are 
detected but unable to be correctly identified, an understanding of the common cathinone 
metabolism could aid in identifying the structure. Therefore an understanding of the metabolites 
generated for a range of cathinone derivatives, as well as their characteristic mass-spectral features 
(i.e. m/z values), could assist in potentially identifying similar, or potentially likely candidates for the 
unknown compound.  
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The fragment ions and the neutral losses described in this review are the most commonly observed 
fragment ions for cathinone derivatives that could facilitate the identification of the structural 
features unique to specific cathinone derivatives. Although cathinone derivatives share a common 
core structure, comparison of the CID mass spectra has indicated that different functional group 
substitutions can lead to different fragmentation pathways. For instance, the production of ions 
associated with the cumulative loss of C4HO2 suggests the loss of a methylenedioxy substitution. 
Therefore, the presence or absence of this specific fragment ion can serve as an indicator for 
identifying the specific class of cathinone compounds. However, it is worth noting that some of the 
fragment ions observed for synthetic cathinones are not unique to cathinones, as some are present 
in other substances. As such, the fragment ions identified in the current literature can be treated 
only as a foundation for structural identification, especially if only a limited number of fragment ions 
are available for analysis. Additionally, as only a selection of generalised fragment ions were 
discussed within this review, additional work that encompasses and compares a broader range of 
synthetic cathinone fragment ions would be beneficial. Further investigation of the fragmentation 
patterns for synthetic cathinone derivatives would be beneficial in order to identify additional 
fragment ions and to further assess the mechanism in which these compounds undergo 
fragmentations and re-arrangements. A greater understanding of these processes could be applied 
for the structural characterisation of cathinone derivatives and assist in the identification of newly-
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